Last night, the abstracts for clinical trials presenting at the 2012 ASCO Genitourinary Cancers Symposium. For now, we want to focus on the most important abstract: Medivation’s (NASDAQ: MDVN) MDV3100 Phase III AFFIRM study of men with castration-resistant prostate cancer(CRPC) that were previously treated with docetaxel. After reviewing the abstract, we believe MDV3100 will replace […]
SNMX – Initiating Coverage on Senomyx
Introduction to Senomyx Senomyx $SNMX is unique from every one of the other companies we cover – while SNMX uses the same tools and techniques of biotech and pharmaceutical drug discovery, they apply these efforts to the discovery of novel food and beverage ingredients. Senomyx develops high throughput assays to screen large compound libraries for […]
CLSN – Quick Take- It’s Bear Territory
CLSN: Quick Take- It’s Bear Territory Overview: Celsion is developing a drug called Thermodox, a heat labile liposomal form of the chemotherapy doxorubicin. Investors are mainly interested in the HEAT trial, a multinational trial in patients with hepatocellular carcinoma (HCC) comparing Thermodox with radiofrequency ablation (RFA) versus RFA alone. The Wrong Endpoint: It does not […]
INFI – Hedgehog inhibitor fails phase 2 trial in pancreatic cancer
Infinity Pharma $INFI announced on January 27th that it was halting a randomized phase 2 trial of the Hedgehog inhibitor saridegib (IPI-926) in metastatic pancreatic cancer, sending the stock down by about 40% to around $6.00 (~$160m market cap). I’ll recap what happened and what is next for INFI based today’s conference call as well […]
ONTY – The Bull Case
The Bull Case Note: We at Chimera are not in complete agreement on ONTY. This is my view. Background: Oncothyreon developed Stimuvax, liposome vaccine (L-BLP25), as a cancer vaccine for the treatment of non-small cell lung cancer (NSCLC), breast cancer, and multiple myeloma. It licensed worldwide rights to Merck KGaA, who has now taking over […]
ARQL – Quick Update on Arqule
On January 17th, ArQule Inc (NASDAQ: ARQL) announced that their Phase 2 trial of ARQ197(Tivantinib) met its primary endpoint in 2nd-line hepatocellular carcinoma(liver cancer). This was somewhat of a surprising results given the difficulty of treating 2nd-line HCC and previous failures in this disease. There are currently no approved drugs for this indication. The recent […]
MNTA – Update on Momenta
Over the past several weeks, Momenta Pharmaceuticals (Nasdaq:MNTA) has had interesting developments on multiple fronts that we want to update subscribers on. Novartis (NYSE:NVS) reported 4Q’11 earnings of $225 million in generic Lovenox sales, which is very high given Sanofi launched an authorized-generic Lovenox briefly. These are very good sales numbers that put Momenta back […]
FOLD – Initiating Coverage
FOLD: Initiating Coverage Overview: Now here is an interesting story. Amicus Therapeutics was founded in 2002 by serial entrepreneur and CEO John Crowley. He had previously founded Novozyme seeking a treatment for his daughter and son, both diagnosed with Pompe disease. The effort led to the discovery of enzyme replacement therapy, Myozyme, now marketed by […]
CBST – 2011 Q4 Quarterly Report Follow-up; Catalysts Through 2012 and Beyond
CBST: 2011 Q4 Quarterly Report Follow-up; Catalysts Through 2012 and Beyond Thursday, January 19 Cubist announced fourth quarter and full-year 2011 results today that surpassed analyst expectations. Excluding one-time costs, quarterly earnings jumped to 66 cents/share from 24 cents the previous year. This was well above consensus estimates of 31 cents. Profit decreased to 11 […]
LXRX – Lexicon Pharmaceuticals is Overvalued
Lexicon Pharma stocks its drug candidate pipeline with a discovery platform based on mouse gene knockout technology, which has allowed them to study the roles of different proteins in disease and select drug targets accordingly. The company’s major clinical programs are headlined by their candidate for type 2 diabetes, LX4211. LXRX has consistently talked about […]
Preview of ASCO 2012 GU Symposium
The 2012 ASCO Genitourinary Cancers Symposium from February 2-4, 2012. The conference is broken down into 3 days focusing on three main areas: Thursday appears dedicated to prostate cancer, Friday is mostly related to urothelial cancers(penile, urethral, urothelial, and testicular), and Saturday is dedicated to kidney cancer. Abstracts will be released on Tuesday, January 31, […]
ASCO Gastrointestinal (GI) Cancer Symposium – Update
Last night (January 17th), the American Society of Clinical Oncology (ASCO) released the full abstracts summarizing the data contained in all presentations at the upcoming ASCO-GI meeting January 19-21, 2012. In our preview post, we highlighted a number of presentations that caught our attention heading into the meeting. Our notes are below; all in all, […]
CBST – Initiating Coverage
CBST: Initiating Coverage Overview: Cubist is a small commercial stage biotech focused on the development of acute care products. Its revenues are almost entirely derived from the antibiotic Cubicin, used for skin and skin-structure infections. The drug has been one of the most successful recent antibiotic launches, allowing Cubist to focus on building up its […]
Anticipated EMA decisions in the first half of 2012
Following our post on upcoming FDA decisions/panel, we wanted to do the same but for European Medicines Agency (EMA) decisions. As you will see, most of the events listed below just have an estimated date by which we will hear an update. This is largely because the way drugs are approved in the EU is […]
ISIS – Research & Development Day Pipeline Recap
Isis Pharma $ISIS held its annual research and development pipeline update for analysts and investors on January 5, 2012. Unfortunately there was no question and answer session, but I’ll review some of the highlights from the two hours of prepared remarks below. An overview of 2012 goals and milestones for the entire antisense pipeline was […]
Upcoming FDA Decisions and Advisory Panels
To help save everyone some time, we went ahead and rounded up the upcoming FDA PDUFA dates and FDA Advisory Committees. We will have trade ideas and opinions on some of these events in the near future. We have highlighted some of those which we feel are the biggest importance to the market with asterisks(*). […]
VVUS – Quick Update – Vivus alters NDA for Qnexa, changes REMS
Vivus Pharmaceuticals (NASDAQ:VVUS) reached an agreement today with the FDA, to alter both it’s REMS and Label for obesity drug candidate, Qnexa. Previous Proposed Label Management took a very conservative approach when filing the initial NDA. Given questions about teratogencity of topiramate, one of the active ingredients in Qnexa, Vivus’s management proposed a label that […]
BMY & INHX – Bristol-Myers Squibb Buys Inhibitex for $2.5 Billion
Bristol-Myers Squibb Buys Inhibitex for $2.5 Billion On Saturday, Bristol announced it would acquire Inhibitex for $26 a share, about $2.5 billion dollars, a 163% premium to the companies $9.87 Friday closing price. Inhibitex had been the hot topic of takeover speculation lately for its HCV drug INX-189, a coveted nucleotide polymerase inhibitor. The hepatitis […]
ACHN & INHX: Two HCV Drugmakers In The Spotlight
ACHN v. INHX: Two HCV Drugmakers In The Spotlight Achillion: On Wednesday January 4, Achillion announced it had received Fast-Track designation from the FDA for its experimental HCV drug ACH-1625. A positive development for sure- investors reacted by lifting the stock 1% on a mostly down day for biotechs. Fast Track status is reserved for […]
Biotech catalysts at two upcoming medical conferences
We want to take a moment to highlight two upcoming oncology focused medical conferences that will showcase data that represent potential catalysts for several biotech companies we’re tracking. First up, we have the 2012 ASCO Gastrointestinal Cancers Symposium from January 19-21, 2012. This conference will be focused on developments in the treatment of cancers of […]
